唑来膦酸联合紫杉醇不同序贯用药方案对前列腺癌DU145细胞的作用

目的 观察唑来膦酸联合紫杉醇不同序贯用药方案对激素非依赖性前列腺癌DU145细胞的作用,以探讨两种药物可能的最佳序贯用药方案.方法 用MTT法和Annexin V-FITC/PI双染色法检测不同序贯用药方案对前列腺癌DU145细胞增殖与凋亡的影响.结果 MTY法检测发现先予紫杉醇再予唑来膦酸组对DU145细胞的生长抑制率为(44.17±5.81)%,作用强于其他两种序贯用药方案(P<0.01).Annexin V-FITC/PI双染色法检测发现先予紫杉醇再予唑来膦酸组能最大限度的诱导前列腺癌细胞的凋亡(14.96%)和死亡(14.37%),作用强于其他用药方案(P<0.05).结论 先予紫杉醇再予唑来膦酸作用于DU145细胞可能是抑制细胞增殖及诱导细胞凋亡的最佳给药方案.

Study of sequence-dependent in vitro effects of zoledronic and and paclitaxel upon DU145 prostate cancer cells

Objective To investigate the anti-proliferation and pro-apoptotic effects of different sequence schemes of zoledronic acid plus paclitaxel upon the hormone-refractory prostate cancer cell lines DU145 in vitro so as to provide the potentially optimal sequence scheme of these two drugs. Methods MTT assay and Annexin V-FITC/PI double-staining flow cytometry were employed to observe the effects of zoledronic acid plus paclitaxel upon anti-proliferation and apoptosis induction respectively. Results Inhibition of cellular growth by (44. 17 ± 5. 81) % was observed under the treatment of paclitaxel and then zoledronic acid. Such a regimen was superior to the treatment of zoledronic acid and then paclitaxel or zoledronic acid (32. 81 ±5. 13)% plus paclitaxel (36.43 ±5. 75)%. In comparisons with other groups, the treatment of paclitaxel and then zoledronic acid induced the maximal apoptosis (14. 96% ) and necrosis (14. 37% ) as shown by Annexin V-FITC/PI double-staining flow cytometry. Conclusion For the maximal anti-proliferation and apoptosis, DU145 cells should be treated with paclitaxel then zoledronic acid. Such a regimen provides the optimal scheme for the sequence-dependent treatment.